Steve B. Warnecke
United States of America
Dr. Ivan Rich, Ph.D. serves as the Chairman of the Board and Chief Executive Officer of HemoGenix, Inc. Dr. Richards founded HemoGenix, Inc. in March 2000. He has been the Senior Director, Pharmacology of Sirna Therapeutics, Inc. since November 4, 2003. He joined Sirna Therapeutics, Inc. from Pfizer Corporation where he made significant contributions as a Distinguished Scientist, Senior Fellow and Discovery Team Leader to numerous therapeutic programs. At Pfizer, he was responsible for pre-clinical drug discovery activities, including Pharmacology, Drug Metabolism and Toxicology. In 1994, he founded and was Chief Executive Officer of "Specialized Culture Technologies". Dr. Rich has extensive experience in the development of drugs in several therapeutic areas including infectious and inflammatory diseases. His postdoctoral research was performed at the University of Chicago between 1981 and 1983. He serves as a Member of Scientific Advisory Board of IR Biosciences Holdings Inc. Dr. Rich serves as an Adjunct Professor in the Department of Biology at the University of Colorado at Colorado Springs. He has authored over 60 peer-reviewed publications and over 100 abstracts throughout his distinguished career. He has authored 32 reviews and book chapters and has attended and presented his research at more than 200 international conferences. He organized and edited conference proceedings for a NATO Advanced Research Workshop. Together with Terrance R.J. Lappin, PhD, Professor of Hematology at Queen's University in Belfast, Northern Ireland, he organized and edited the proceedings of a New York Academy of Science Workshop on erythropoietin. Dr. Rich received his Ph.D. in Pharmacology from the Royal College of Surgeons in the United Kingdom. Dr. Rich obtained his BSc in biochemistry at the University of Sussex in Brighton/Falmer, England in 1973. He completed his PhD in 1978 at the University of Ulm in Ulm, Germany and completed a second thesis in Experimental Hematology in 1995.